TAK-653

TAK-653, known by the international nonproprietary name osavampator and also designated NBI-1065845, is an investigational small-molecule positive allosteric modulator (PAM) of the AMPA subtype of glutamate receptor ^[3][4]. It was discovered by Takeda Pharmaceutical Company and later advanced by Neurocrine Biosciences in clinical development for major depressive disorder (MDD) ^[4][7].

AMPA receptors mediate the majority of fast excitatory synaptic transmission in the brain, and their activation is now understood to be a common downstream trigger for the rapid antidepressant effects of ketamine and related agents ^[3][8]. Earlier AMPA receptor potentiators, historically called ampakines, tended to carry intrinsic agonist activity, which was associated with a narrow bell-shaped dose-response curve and a heightened seizure risk ^[3]. TAK-653 was deliberately screened and optimized to have minimal agonistic activity, potentiating the receptor only in the presence of glutamate through a structural interaction at the GluA1 subunit; this design aims to preserve the physiological pattern of synaptic signaling while widening the safety margin ^[1][3].

The compound has been characterized extensively in preclinical models, where it enhances synaptic responses and cognition and produces antidepressant-like effects, and it has progressed through phase 1 human pharmacokinetic studies and into phase 2 trials for depression ^[1][4][5]. In early human studies it was generally well tolerated and showed no meaningful cytochrome P450 3A induction, supporting co-administration with other medications ^[4]. As an experimental agent, osavampator is not approved for medical use and remains confined to clinical research; it is administered orally in trial settings ^[4].

REGULATORY: investigational only. Not approved by FDA, EMA, PMDA or any other authority. Not a scheduled or controlled substance in the United States. Not named on the WADA Prohibited List, but it is captured by class S0 Non-Approved Substances, which prohibits at all times "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development...)"; a tested athlete taking it commits an anti-doping rule violation. Any material sold to consumers is unlicensed research chemical, not a clinical preparation.

HUMAN ADVERSE EFFECTS: in Phase 1 (NCT02561156, posted results) there were zero serious adverse events across all doses up to 18 mg single and 9 mg daily; the commonest events were headache (17 participants) and dizziness (13), both also common on placebo. Single cases of palpitations at 9 mg, sinus tachycardia and anxiety at 5 mg, presyncope at 3 mg, asthenia and lethargy at 9 mg daily. One participant recorded an "electroencephalogram abnormal" adverse event at 5 mg, but zero participants in either part met the criterion for a clinically significant EEG change, and zero had treatment-emergent suicidal ideation on the C-SSRS. One discontinuation for an adverse event, in the 6 mg multiple-dose cohort (16.7% of that cohort of six).

In Phase 2 (n=183) the sponsor reports no serious adverse events and no adverse events of special interest; headache 11.1% at 1 mg and 4.3% at 3 mg, nasopharyngitis 4.4% and 6.4%. CNS profile in healthy volunteers was psychostimulant-like on the NeuroCart battery, with improved adaptive tracking and increased saccadic peak velocity but no subjective drug effect and no body sway.

INTERACTIONS: TAK-653 is not a CYP3A inducer; after 10 days of dosing, midazolam AUC ratio was 0.88, ethinyl estradiol AUC ratio 1.01 and levonorgestrel AUClast ratio 0.87, so no clinically meaningful loss of oral contraceptive exposure (PMID 38700236). No other human interaction data exists.

CLASS RISK: AMPA receptor potentiators as a class have caused seizures and narrow therapeutic windows; TAK-653 caused tonic-clonic convulsions in one rat only at 100 mg/kg orally, giving margins of 419-fold on plasma Cmax and 1017-fold on AUC, versus 42-fold and 122-fold for TAK-137 and 3.4-fold and 4.0-fold for LY451646. Those margins are rat data and have not been reproduced in humans. Long-term human safety is unknown; the open-label Phase 3 safety study (NCT06966401) does not complete until 2029.

The one formal interaction study run on TAK-653 asked whether it induces CYP3A, the enzyme that clears a large share of ordinary medication. It does not. In a phase I trial, healthy adults took TAK-653 for nine days before receiving either midazolam, a sensitive CYP3A substrate used as the standard probe, or a combined oral contraceptive. Exposure barely moved in any arm; the geometric mean ratios sat between 0.87 and 1.01, with confidence intervals spanning 1.0 ^[4]. Contraceptive levels in particular were unchanged, which is the practical question, since an inducer would quietly reduce their effectiveness.

That is the extent of the documented record. TAK-653 is investigational, so there is no interactions section on any label and no post-marketing reporting; nothing is known about combining it with the compounds people actually pair it with. The absence of findings here reflects an absence of study, not a clean bill.

Checking a whole stack? Run it through interactions + stacks.

TAK-653, also known as osavampator and NBI-1065845, was discovered by Takeda Pharmaceutical Company through a screening program aimed at finding an AMPA receptor potentiator with minimal intrinsic agonist activity, a property intended to avoid the narrow dose-response and seizure liability that limited earlier ampakines. Preclinical work published in 2021 and 2022 described its glutamate-dependent mechanism, its engagement of the Akt, ERK, mTOR, and BDNF cascade implicated in rapid antidepressant action, and a wide safety margin against convulsions. The compound was subsequently licensed to Neurocrine Biosciences and advanced into phase II clinical development for major depressive disorder, with phase I studies confirming favorable tolerability and no meaningful cytochrome P450 3A interaction. It remains investigational, with efficacy in patients still being established.

TAK-653 is viewed as a genuinely next-generation ampakine, engineered to deliver the synaptic and BDNF-boosting benefits associated with ketamine's mechanism while sidestepping the agonist baggage and seizure risk that troubled its predecessors. Its striking preclinical safety margin against convulsions and its clean phase I tolerability profile have helped it become one of the more credible rapid-acting antidepressant candidates to reach mid-stage trials. The measured view is that its antidepressant and pro-cognitive promise, though well supported in cells and animals, still awaits confirmation of efficacy in patients through ongoing clinical work. As a designed, glutamate-dependent potentiator with a real development pipeline, it stands out from the typical research chemical.